AtCor forecasts profit in 2013
31 January, 2013 by Tim DeanMedical device manufacturer AtCor (ASX:ACG) expects to report a profit in this financial year following strong sales of its SphygmoCor diagnostic device.
The rise of smartphone health and medical apps
31 January, 2013 by Michael Sutton and Megan FraserHealth and medical smartphone apps can help improve the management of acute and chronic conditions and provide more personalised medical treatment.
State of the industry to be gauged by its leaders in annual survey
30 January, 2013 by AusBiotechAusBiotech is pleased to once again conduct the annual CEO Industry Position Survey 2013 to get a comprehensive view of the Australian biotechnology sector.
Mesoblast gets FDA all-clear for arthritis stem cell trial
30 January, 2013 by Dylan Bushell-EmblingThe FDA has approved Mesoblast’s (ASX:MSB) application to conduct a phase II trial of its mesenchymal precursor cells to treat rheumatoid arthritis.
Major medtech conference moves to Victoria
30 January, 2013 by AusBiotechAusMedtech 2013, Australia’s premier medical technology conference, will be held in Melbourne for the first time on 15-16 May, with the support of the state government of Victoria.
Biotechs up after All Ordinaries surge
30 January, 2013 by Tim DeanLife science stocks have enjoyed a boost alongside the broader share market, with stocks such as CSL (ASX:CSL) hitting historic highs.
FDA panel to vote on Pharmaxis’s NDA
30 January, 2013 by Dylan Bushell-EmblingAn independent advisory panel will vote today on whether to recommend the US FDA approve Pharmaxis’s (ASX:PSX) NDA for Bronchitol as a cystic fibrosis treatment.
ResMed revenues up thanks to strong sales
30 January, 2013 by Tim DeanResMed (ASX:RMD) has seen revenues increase by 13% for the December quarter year on year with a dividend coming in February.
Cellmid antibodies reduced kidney damage in mice
24 January, 2013 by Dylan Bushell-EmblingCellmid’s (ASX:CDY) anti-midkine antibodies were able to reduce kidney damage and preserve function in an animal model of diabetic nephropathy.
Uscom protocol slashed sepsis deaths: study
23 January, 2013 by Dylan Bushell-EmblingA Bathurst hospital reduced sepsis-related deaths by 94% by adopting a treatment protocol involving the use of Uscom (ASX:UCM) diagnostics tech, according to a new study.
Allied Healthcare closes $4.6m capital raising
23 January, 2013 by Dylan Bushell-EmblingAllied Healthcare (ASX:AHZ) will put the $4.6m raised in a placement and SPP towards launching its CardioCel heart patch as well as phase I trials of its DNA vaccine against herpes.
Abraxane extends life in advanced pancreatic cancer patients
23 January, 2013 by Tim DeanA phase III trial has shown Celgene’s Abraxane, distributed here by Specialised Therapeutics, has a significant impact on survival in patients with advanced pancreatic cancer.
Universal Biosensors expecting to launch new diagnostic in 2013
22 January, 2013 by Tim DeanUniversal Biosensors (ASX:UBI), in partnership with Siemens, expects to see its blood coagulation product hit the shelves this year, further boosting revenues for the company.
AusBiotech to host inaugural Australia China Life Science Summit
22 January, 2013 by AusBiotechAusBiotech will hold the inaugural Australia China Life Science Summit to share knowledge and gain expert views from others who have successfully created linkages and developed partnerships in the region.
Another European regulatory milestone for pSivida's Iluvien
18 January, 2013 by Tim DeanSpain's regulator has awarded marketing approval to pSivida's (ASX:PVA) Iluvien, leaving just Italy yet to give the treatment the tick ahead of a launch early this year.
